• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一氧化氮鼻喷剂(NONS)治疗轻度 COVID-19 感染的临床疗效。

Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.

机构信息

Consultant Medical Virologist, Frimley Health NHS Foundation Trust, Portsmouth Road, Camberley, Surrey GU16 7UJ, United Kingdom.

Medical Student, University of Cambridge School of Clinical Medicine, Box 111 Cambridge Biomedical Campus, Cambridge CB2 0SP, United Kingdom.

出版信息

J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.009. Epub 2021 May 13.

DOI:10.1016/j.jinf.2021.05.009
PMID:33992687
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8117664/
Abstract

Baek et al. investigated the duration of COVID-19 virus shedding in infected patients and demonstrated that even in patients demonstrating prolonged viral clearance, the virus was no longer viable after 15 days post onset of symptoms. Our study aimed to measure whether nitric oxide nasal spray (NONS) further accelerates this reduction in SARS-CoV-2 RNA load versus a control arm with saline spray. Our study recruited 80 participants who were divided into a NONS treatment arm or a placebo arm to test the efficacy of NONS as a treatment for mild COVID-19 infection.

摘要

贝克等人研究了感染患者体内 COVID-19 病毒的脱落时间,结果表明,即使在病毒清除时间延长的患者中,症状出现 15 天后病毒也不再具有活性。我们的研究旨在测量与生理盐水喷雾的对照组相比,一氧化氮鼻腔喷雾(NONS)是否进一步加速 SARS-CoV-2 RNA 载量的降低。我们的研究招募了 80 名参与者,他们被分为 NONS 治疗组或安慰剂组,以测试 NONS 作为轻度 COVID-19 感染治疗的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2d8/8117664/8db25355a860/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2d8/8117664/8db25355a860/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2d8/8117664/8db25355a860/gr1_lrg.jpg

相似文献

1
Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.一氧化氮鼻喷剂(NONS)治疗轻度 COVID-19 感染的临床疗效。
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.009. Epub 2021 May 13.
2
SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial.使用新型一氧化氮鼻喷雾剂(NONS)治疗加速严重急性呼吸综合征冠状病毒2(SARS-CoV-2)清除:一项随机试验。
Lancet Reg Health Southeast Asia. 2022 Aug;3:100036. doi: 10.1016/j.lansea.2022.100036. Epub 2022 Jun 29.
3
Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2.0.5%聚维酮碘鼻腔喷雾剂(Nasodine®)对新型冠状病毒脱落影响的II期试验
Laryngoscope. 2024 Sep;134(9):3947-3952. doi: 10.1002/lary.31430. Epub 2024 Mar 30.
4
Nasal spray of an IgM-like ACE2 fusion protein HH-120 accelerates SARS-CoV-2 clearance: A single-center propensity score-matched cohort study.鼻腔喷雾 IgM 样 ACE2 融合蛋白 HH-120 加速 SARS-CoV-2 清除:一项单中心倾向评分匹配队列研究。
J Med Virol. 2023 May;95(5):e28805. doi: 10.1002/jmv.28805.
5
Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control.天然鼻腔喷雾;一种用于 COVID-19 疾病控制的建议方法。
Infect Disord Drug Targets. 2021;21(8):e160921191568. doi: 10.2174/1871526521666210218201113.
6
Nitric Oxide and its Derivatives Containing Nasal Spray and Inhalation Therapy for the Treatment of COVID-19.一氧化氮及其衍生物的鼻腔喷雾剂和吸入疗法用于治疗新冠肺炎。
Curr Pharm Des. 2022;28(46):3658-3670. doi: 10.2174/1381612829666221024124848.
7
The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial.聚维酮碘鼻腔喷雾对鼻咽 SARS-CoV-2 病毒载量的影响:一项随机对照试验。
Laryngoscope. 2022 Nov;132(11):2089-2095. doi: 10.1002/lary.29935. Epub 2021 Nov 9.
8
Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial.新型冠状病毒肺炎患者经口及鼻腔用酞菁口腔抗菌溶液对 SARS-CoV-2 感染力的影响:一项随机对照试验。
Ger Med Sci. 2023 Jun 23;21:Doc07. doi: 10.3205/000321. eCollection 2023.
9
Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2.鼻腔喷雾剂对严重急性呼吸综合征冠状病毒 2 型的抗病毒活性。
J Hosp Infect. 2022 Feb;120:9-13. doi: 10.1016/j.jhin.2021.10.019. Epub 2021 Nov 6.
10
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.早期使用氮卓斯汀鼻喷剂干预可能会降低 SARS-CoV-2 感染患者的病毒载量。
Sci Rep. 2023 Apr 26;13(1):6839. doi: 10.1038/s41598-023-32546-z.

引用本文的文献

1
Nasal Emulgel's Role in Preventing Coronavirus Infection.鼻用乳胶凝胶在预防冠状病毒感染中的作用。
Pharmaceutics. 2025 Jun 19;17(6):795. doi: 10.3390/pharmaceutics17060795.
2
Hydrogen sulfide (H2S) coordinates redox balance, carbon metabolism, and mitochondrial bioenergetics to suppress SARS-CoV-2 infection.硫化氢(H2S)协调氧化还原平衡、碳代谢和线粒体生物能量学以抑制新型冠状病毒2(SARS-CoV-2)感染。
PLoS Pathog. 2025 May 19;21(5):e1013164. doi: 10.1371/journal.ppat.1013164. eCollection 2025 May.
3
The therapeutic potential of signaling gases in COVID-19.

本文引用的文献

1
Duration of culturable SARS-CoV-2 within different specimens among mild and severe COVID-19 patients: A longitudinal study.轻度和重度新冠肺炎患者不同样本中可培养的严重急性呼吸综合征冠状病毒2的持续时间:一项纵向研究。
J Infect. 2021 Jul;83(1):e29-e31. doi: 10.1016/j.jinf.2021.04.025. Epub 2021 Apr 28.
2
Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study.西班牙加泰罗尼亚 282 起聚集性 COVID-19 传播:一项队列研究。
Lancet Infect Dis. 2021 May;21(5):629-636. doi: 10.1016/S1473-3099(20)30985-3. Epub 2021 Feb 2.
3
SARS-CoV-2 detection, viral load and infectivity over the course of an infection.
信号气体在新冠病毒肺炎中的治疗潜力
Med Gas Res. 2024 Sep 1;14(3):151-152. doi: 10.4103/2045-9912.390250. Epub 2024 Mar 20.
4
Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.阿扎司汀鼻喷雾剂用于非住院轻度新型冠状病毒肺炎感染患者:一项随机、安慰剂对照、平行组、多中心II期临床试验。
Viruses. 2024 Dec 13;16(12):1914. doi: 10.3390/v16121914.
5
Astodrimer Sodium Nasal Spray versus Placebo in Non-Hospitalised Patients with COVID-19: A Randomised, Double-Blinded, Placebo-Controlled Trial.阿斯托地瑞钠鼻喷雾剂与安慰剂用于非住院COVID-19患者的对照研究:一项随机、双盲、安慰剂对照试验
Pharmaceutics. 2024 Sep 6;16(9):1173. doi: 10.3390/pharmaceutics16091173.
6
Whole-Genome Deep Sequencing of the Healthy Adult Nasal Microbiome.健康成人鼻腔微生物群的全基因组深度测序
Microorganisms. 2024 Jul 12;12(7):1407. doi: 10.3390/microorganisms12071407.
7
A perspective current and past modes of inhalation therapy.吸入疗法的现状和过去模式透视。
Microb Biotechnol. 2024 Feb;17(2):e14419. doi: 10.1111/1751-7915.14419.
8
The Potential Role of Nitric Oxide as a Therapeutic Agent against SARS-CoV-2 Infection.一氧化氮作为治疗 SARS-CoV-2 感染的潜在药物的作用。
Int J Mol Sci. 2023 Dec 5;24(24):17162. doi: 10.3390/ijms242417162.
9
Saying no to SARS-CoV-2: the potential of nitric oxide in the treatment of COVID-19 pneumonia.拒绝 SARS-CoV-2:一氧化氮在治疗 COVID-19 肺炎中的潜力。
Med Gas Res. 2024 Apr-Jun;14(2):39-47. doi: 10.4103/2045-9912.385414.
10
Inhaled nitric oxide: can it serve as a savior for COVID-19 and related respiratory and cardiovascular diseases?吸入一氧化氮:它能成为治疗新冠肺炎及相关呼吸和心血管疾病的救星吗?
Front Microbiol. 2023 Oct 2;14:1277552. doi: 10.3389/fmicb.2023.1277552. eCollection 2023.
在感染过程中对 SARS-CoV-2 的检测、病毒载量和传染性。
J Infect. 2020 Sep;81(3):357-371. doi: 10.1016/j.jinf.2020.06.067. Epub 2020 Jun 29.
4
Safety, bioavailability and mechanism of action of nitric oxide to control Bovine Respiratory Disease Complex in calves entering a feedlot.一氧化氮用于控制进入饲养场的犊牛牛呼吸道疾病综合征的安全性、生物利用度及作用机制。
Res Vet Sci. 2014 Apr;96(2):328-37. doi: 10.1016/j.rvsc.2013.12.012. Epub 2013 Dec 30.
5
Gaseous nitric oxide reduces influenza infectivity in vitro.气态一氧化氮可降低流感病毒的体外感染力。
Nitric Oxide. 2013 May 31;31:48-53. doi: 10.1016/j.niox.2013.03.007. Epub 2013 Apr 2.
6
Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity.视角系列:宿主/病原体相互作用。一氧化氮相关抗菌活性的机制。
J Clin Invest. 1997 Jun 15;99(12):2818-25. doi: 10.1172/JCI119473.
7
Endogenous nitric oxide: physiology, pathology and clinical relevance.内源性一氧化氮:生理学、病理学及临床相关性
Eur J Clin Invest. 1991 Aug;21(4):361-74. doi: 10.1111/j.1365-2362.1991.tb01383.x.